|Bid||0.2300 x N/A|
|Ask||0.2400 x N/A|
|Day's Range||0.2200 - 0.2500|
|52 Week Range||0.1400 - 0.7800|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Announced today that the US Food and Drug Administration ("FDA") has provided its official Written Response ...
BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF) ("BioVaxys"), is pleased to announce today that the US Food and Drug Administration ("FDA") has provided its official Written Response to the Company's request for a Pre-IND Type B review of CoviDTH as a diagnostic for evaluating T-cell immune response to SARS-CoV-2.